could have a significant impact on cutting the rate of cervical cancer worldwide, because a single dose would simplify the vaccination process and cost less. Cervical cancer is the fourth most common type of cancer among women, killing an estimated 342,000 worldwide in 2020.
The vaccine prevents transmission of cancer-causing strains of the sexually transmitted disease called human papillomavirus, or HPV. The first HPV vaccine was approved in the U.S. in 2006, and the CDC currently recommends two or three doses, depending on a person’s age. The new findings were presented at the end of April during the 35th International Papillomavirus Conference in Washington, DC. The study included 2,275 people in Kenya who ranged in age from 15 to 20 years old. They were randomly assigned to receive one of three treatments: a single-dose vaccine that targets two HPV strains, a single-dose HPV vaccine that targets nine strains, or a control vaccine. Participants were regularly tested for 3 years.
“Following the WHO recommendation in support of a one-dose regimen for HPV vaccine could help make the vaccine more accessible to women and girls around the world by lowering costs, alleviating pressure on supply, and making the vaccine easier to deliver,” Peter Dull, MD, deputy director for clinical vaccine development at the Bill & Melinda Gates Foundation, which funded the research, said in a statement..
Massachusetts General Hospital: “Research Spotlight: Single Dose of HPV is Highly Efficacious in Protecting Young Women.”The New York Times© 2023 WebMD, LLC. All rights reserved.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: SciTechDaily1 - 🏆 84. / 68 Read more »